CA3240163A1 - Inhibiteurs de la phosphorylation anormale et de l'agregation de la proteine tau - Google Patents

Inhibiteurs de la phosphorylation anormale et de l'agregation de la proteine tau Download PDF

Info

Publication number
CA3240163A1
CA3240163A1 CA3240163A CA3240163A CA3240163A1 CA 3240163 A1 CA3240163 A1 CA 3240163A1 CA 3240163 A CA3240163 A CA 3240163A CA 3240163 A CA3240163 A CA 3240163A CA 3240163 A1 CA3240163 A1 CA 3240163A1
Authority
CA
Canada
Prior art keywords
compound
tau
group
formula
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3240163A
Other languages
English (en)
French (fr)
Inventor
Anne Wadouachi
Dulce PAPY GARCIA
Gwladys POURCEAU
Sandrine CHANTEPIE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Université de Picardie Jules Verne
Université Paris-Est Créteil Val de Marne
Original Assignee
Centre National de la Recherche Scientifique
Université de Picardie Jules Verne
Université Paris-Est Créteil Val de Marne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Université de Picardie Jules Verne, Université Paris-Est Créteil Val de Marne filed Critical Centre National de la Recherche Scientifique
Publication of CA3240163A1 publication Critical patent/CA3240163A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA3240163A 2021-11-29 2022-11-29 Inhibiteurs de la phosphorylation anormale et de l'agregation de la proteine tau Pending CA3240163A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21306658.2 2021-11-29
EP21306658 2021-11-29
PCT/EP2022/083709 WO2023094699A1 (fr) 2021-11-29 2022-11-29 Inhibiteurs de la phosphorylation anormale et de l'agrégation de la protéine tau

Publications (1)

Publication Number Publication Date
CA3240163A1 true CA3240163A1 (fr) 2023-06-01

Family

ID=78851140

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3240163A Pending CA3240163A1 (fr) 2021-11-29 2022-11-29 Inhibiteurs de la phosphorylation anormale et de l'agregation de la proteine tau

Country Status (6)

Country Link
US (1) US20250034194A1 (cg-RX-API-DMAC10.html)
EP (1) EP4441064A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024543187A (cg-RX-API-DMAC10.html)
CN (1) CN118922429A (cg-RX-API-DMAC10.html)
CA (1) CA3240163A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023094699A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240409505A1 (en) * 2023-06-12 2024-12-12 The Procter & Gamble Company Gluconamide sulfate surfactants

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686603A (en) * 1995-05-04 1997-11-11 Lever Brothers Company, Division Of Conopco, Inc. Sulfated polyhydroxy compounds as anionic surfactants and a process for their manufacture
WO2007115372A1 (en) * 2006-04-10 2007-10-18 Monash University A method of modulating beta-amyloid peptide production

Also Published As

Publication number Publication date
CN118922429A (zh) 2024-11-08
US20250034194A1 (en) 2025-01-30
WO2023094699A1 (fr) 2023-06-01
JP2024543187A (ja) 2024-11-19
EP4441064A1 (fr) 2024-10-09

Similar Documents

Publication Publication Date Title
Vuong et al. Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies
EP3116511B1 (en) Compositions of selenoorganic compounds and methods of use thereof
RU2663127C2 (ru) Селенсодержащие композиции и их применение для лечения и предотвращения заболеваний или состояний, связанных с митохондриальной дисфункцией
CN109640967B (zh) 抑制胆碱向三甲胺(tma)的转化的方法
CN106456699A (zh) 作为抗老化剂抑制抗凋亡的Bcl‑2蛋白的组合物和方法
Colle et al. Succinobucol, a lipid-lowering drug, protects against 3-nitropropionic acid-induced mitochondrial dysfunction and oxidative stress in SH-SY5Y cells via upregulation of glutathione levels and glutamate cysteine ligase activity
EP1231916A2 (fr) Utilisation de derives d'indirubine pour la fabrication de medicaments
Cao et al. Derivatives of sarcodonin A isolated from Sarcodon scabrosus reversed LPS-induced M1 polarization in microglia through MAPK/NF-κB pathway
Li et al. Discovery of novel SS-31 (d-Arg-dimethylTyr-Lys-Phe-NH2) derivatives as potent agents to ameliorate inflammation and increase mitochondrial ATP synthesis
US20220249411A1 (en) Calixarene compounds and uses thereof
Hwang et al. Synthetic phytoceramides induce apoptosis with higher potency than ceramides
EP4441064A1 (fr) Inhibiteurs de la phosphorylation anormale et de l'agrégation de la protéine tau
CN111344016B (zh) 用于抑制胆碱向三甲胺(tma)的转化的方法
Li et al. A mitochondria-targeted idebenone derivative W1a mitigates cerebral ischemia-reperfusion injury by preserving mitochondrial integrity and suppressing neuroinflammation
KR102874460B1 (ko) Aspergillus sp. SF-7402 유래 화합물을 포함하는 신경퇴행성 질환의 예방 또는 치료용 조성물
EP4291217B1 (fr) Composition thérapeutique à base de feuilles de neurolaena inhibitrice de la dhodh pour le traitement d'infections par virus à arn
KR102917789B1 (ko) 신규한 라말린 유도체 및 이의 퇴행성 뇌질환의 예방 또는 치료 용도
RU2744453C2 (ru) Таргетная неинвазивная трансплантация в мозг функционально активных митохондрий для лечения нейродегенеративных заболеваний
US20240398889A1 (en) Nutraceutical composition and method for the protection of human arterial endothelial cells from endothelial cell dysfunction
Babylon et al. Hesperetin Nanocrystals Improve Mitochondrial Function in a Cell Model of Early Alzheimer Disease. Antioxidants 2021, 10, 1003
EP4499225A1 (en) Phialomustin b (1) for treatment of parkinson's disease (pd) and amyotrophic lateral sclerosis (als)
FR3110395A1 (fr) Composition comprenant un composé ascorbo-camphorate métallique pour son utilisation dans le traitement des infections causées par papillomavirus
EP4408410A1 (fr) Inhibiteurs de l'interaction entre les protéines kinases rock et pdk1
FR3121038A1 (fr) Composition pharmaceutique destinée à inhiber l’infectiosité des virus à bicouche lipidique, à traiter les maladies associées et leurs complications.
EP3600296A1 (fr) Nouveaux composes, compositions et methodes pour le traitement de la resistance a l'insuline

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241120

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241120